menu
    • menu
    [{"orgOrder":0,"company":"AGC Biologics","sponsor":"Horizon Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Partnership","leadProduct":"Teprotumumab","moa":"IGF-1 receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"AGC Biologics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"AGC Biologics \/ Horizon Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"AGC Biologics \/ Horizon Therapeutics"},{"orgOrder":0,"company":"AGC Biologics","sponsor":"Genenta Science","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2025","type":"Agreement","leadProduct":"Pembrolizumab","moa":"||IFNAR","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"AGC Biologics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AGC Biologics \/ Genenta Science","highestDevelopmentStatusID":"7","companyTruncated":"AGC Biologics \/ Genenta Science"},{"orgOrder":0,"company":"AGC Biologics","sponsor":"Trefoil Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Protein","year":"2020","type":"Collaboration","leadProduct":"TTHX1114","moa":"FGF1","graph1":"Ophthalmology","graph2":"IND Enabling","graph3":"AGC Biologics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intracameral Injection","sponsorNew":"AGC Biologics \/ Trefoil Therapeutics","highestDevelopmentStatusID":"5","companyTruncated":"AGC Biologics \/ Trefoil Therapeutics"},{"orgOrder":0,"company":"AGC Biologics","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Partnership","leadProduct":"Tozinameran","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"AGC Biologics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"AGC Biologics \/ Pfizer Inc","highestDevelopmentStatusID":"15","companyTruncated":"AGC Biologics \/ Pfizer Inc"},{"orgOrder":0,"company":"AGC Biologics","sponsor":"Novavax","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Collaboration","leadProduct":"Matrix-M Vaccine, Adjuvanted","moa":"||SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"AGC Biologics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"AGC Biologics \/ Novavax","highestDevelopmentStatusID":"7","companyTruncated":"AGC Biologics \/ Novavax"},{"orgOrder":0,"company":"AGC Biologics","sponsor":"Novavax","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Partnership","leadProduct":"Matrix-M","moa":"||SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"AGC Biologics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"AGC Biologics \/ Novavax","highestDevelopmentStatusID":"7","companyTruncated":"AGC Biologics \/ Novavax"},{"orgOrder":0,"company":"AGC Biologics","sponsor":"Molecular Partners","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Protein","year":"2020","type":"Collaboration","leadProduct":"Ensovibep","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"AGC Biologics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AGC Biologics \/ Molecular Partners","highestDevelopmentStatusID":"4","companyTruncated":"AGC Biologics \/ Molecular Partners"},{"orgOrder":0,"company":"AGC Biologics","sponsor":"Saiba AG","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Partnership","leadProduct":"Virus-like Particle Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"AGC Biologics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AGC Biologics \/ Saiba AG","highestDevelopmentStatusID":"4","companyTruncated":"AGC Biologics \/ Saiba AG"},{"orgOrder":0,"company":"AGC Biologics","sponsor":"AdaptVac","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Agreement","leadProduct":"SARS-CoV-2 Capsid-Virus-like Particle Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"AGC Biologics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AGC Biologics \/ AdaptVac","highestDevelopmentStatusID":"1","companyTruncated":"AGC Biologics \/ AdaptVac"},{"orgOrder":0,"company":"AGC Biologics","sponsor":"Takara Bio","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Partnership","leadProduct":"Plasmid Dna Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"AGC Biologics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AGC Biologics \/ Takara Bio","highestDevelopmentStatusID":"1","companyTruncated":"AGC Biologics \/ Takara Bio"},{"orgOrder":0,"company":"AGC Biologics","sponsor":"Provention Bio","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Agreement","leadProduct":"Teplizumab","moa":"CD3","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"AGC Biologics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AGC Biologics \/ Provention Bio","highestDevelopmentStatusID":"15","companyTruncated":"AGC Biologics \/ Provention Bio"},{"orgOrder":0,"company":"AGC Biologics","sponsor":"Oculis","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Partnership","leadProduct":"Licaminlimab","moa":"TNF-alpha receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"AGC Biologics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Suspension","sponsorNew":"AGC Biologics \/ Oculis","highestDevelopmentStatusID":"8","companyTruncated":"AGC Biologics \/ Oculis"},{"orgOrder":0,"company":"AGC Biologics","sponsor":"Pierre Fabre","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Protein","year":"2020","type":"Partnership","leadProduct":"ER-004","moa":"EDA1","graph1":"Rare Diseases and Disorders","graph2":"Phase I","graph3":"AGC Biologics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intra-amniotic Injection","sponsorNew":"AGC Biologics \/ Pierre Fabre","highestDevelopmentStatusID":"6","companyTruncated":"AGC Biologics \/ Pierre Fabre"},{"orgOrder":0,"company":"AGC Biologics","sponsor":"Rocket Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Partnership","leadProduct":"RP-L102","moa":"Undisclosed","graph1":"Rare Diseases and Disorders","graph2":"Phase II","graph3":"AGC Biologics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AGC Biologics \/ Rocket Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"AGC Biologics \/ Rocket Pharmaceuticals"},{"orgOrder":0,"company":"AGC Biologics","sponsor":"The Jikei University","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Discovery","graph3":"AGC Biologics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"AGC Biologics \/ The Jikei University","highestDevelopmentStatusID":"2","companyTruncated":"AGC Biologics \/ The Jikei University"},{"orgOrder":0,"company":"AGC Biologics","sponsor":"Medigene","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Agreement","leadProduct":"MDG1015","moa":"||NY-ESO-1\/LAGE-1a","graph1":"Oncology","graph2":"IND Enabling","graph3":"AGC Biologics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AGC Biologics \/ Medigene","highestDevelopmentStatusID":"5","companyTruncated":"AGC Biologics \/ Medigene"},{"orgOrder":0,"company":"AGC Biologics","sponsor":"Faron Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Agreement","leadProduct":"Clevegen","moa":"Clever-1-positive TAMs","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"AGC Biologics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AGC Biologics \/ Faron Pharmaceuticals","highestDevelopmentStatusID":"7","companyTruncated":"AGC Biologics \/ Faron Pharmaceuticals"},{"orgOrder":0,"company":"AGC Biologics","sponsor":"Allergy Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Partnership","leadProduct":"VLP-based Peanut Allergy Vaccine","moa":"Undisclosed","graph1":"Immunology","graph2":"IND Enabling","graph3":"AGC Biologics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"AGC Biologics \/ Allergy Therapeutics","highestDevelopmentStatusID":"5","companyTruncated":"AGC Biologics \/ Allergy Therapeutics"}]

    Find Clinical Drug Pipeline Developments & Deals by AGC Biologics

    Menu

    AGC Biologics

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    SERVICES

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            AGC Biologics

                            U.S.A arrow
                            AACR Annual meeting
                            Not Confirmed

                            AGC Biologics

                            U.S.A arrow
                            AACR Annual meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Temferon,Pembrolizumab

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Genenta Science

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Genenta Strengthens Agreement with AGC Biologics to Boost Cell Therapy Manufacturing

                            Details : Un der the agreement, AGC will support the Genenta to advance their pipeline product Temferon, which is being evaluated for the treatment of methastatic Renal Cell Cancer.

                            Product Name : Undisclosed

                            Product Type : Cell and Gene therapy

                            Upfront Cash : Undisclosed

                            January 09, 2025

                            Lead Product(s) : Temferon,Pembrolizumab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Genenta Science

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            AGC Biologics

                            U.S.A arrow
                            AACR Annual meeting
                            Not Confirmed

                            AGC Biologics

                            U.S.A arrow
                            AACR Annual meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : MDG1015,PD1-41BB

                            Therapeutic Area : Oncology

                            Study Phase : IND Enabling

                            Sponsor : Medigene

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            AGC Biologics Signs TCR-T Cell Services Agreement to Support Medigene’s New Cell Therapy Product

                            Details : Under the agreement, AGC Biologics is providing autologous production for MDG1015, a third generation TCR-T therapy, focused on the treatment of solid cancers, supporting Medigene’s IND filing and clinical trials.

                            Product Name : MDG1015

                            Product Type : Cell and Gene therapy

                            Upfront Cash : Undisclosed

                            October 25, 2023

                            Lead Product(s) : MDG1015,PD1-41BB

                            Therapeutic Area : Oncology

                            Highest Development Status : IND Enabling

                            Sponsor : Medigene

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            AGC Biologics

                            U.S.A arrow
                            AACR Annual meeting
                            Not Confirmed

                            AGC Biologics

                            U.S.A arrow
                            AACR Annual meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Study Phase : Discovery

                            Sponsor : The Jikei University

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            AGC Biologics Signs Exosome Agreement with The Jikei University in Japan for Idiopathic Pulmonary Fibrosis (IP...

                            Details : Under the agreement, AGC Biologics will assume a technology transfer and feasibility study for a drug product focused on the treatment of Idiopathic pulmonary fibrosis at the CDMO's center of Cell and Gene Excellence in Milan.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Undisclosed

                            March 04, 2023

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Highest Development Status : Discovery

                            Sponsor : The Jikei University

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            AGC Biologics

                            U.S.A arrow
                            AACR Annual meeting
                            Not Confirmed

                            AGC Biologics

                            U.S.A arrow
                            AACR Annual meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Teplizumab

                            Therapeutic Area : Endocrinology

                            Study Phase : Approved FDF

                            Sponsor : Provention Bio

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            AGC Biologics to Commercial Manufacture Provention Bio Diabetes Therapy

                            Details : Under the agreement, AGC Biologics will manufacture TZIELD™ (teplizumab-mzwv), a new T1D treatment. TZIELD is the first and only immunomodulatory treatment that delays the onset of Stage 3 T1D in adult and pediatric patients aged 8 years and older.

                            Product Name : Tzield

                            Product Type : Antibody

                            Upfront Cash : Undisclosed

                            January 24, 2023

                            Lead Product(s) : Teplizumab

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Approved FDF

                            Sponsor : Provention Bio

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            AGC Biologics

                            U.S.A arrow
                            AACR Annual meeting
                            Not Confirmed

                            AGC Biologics

                            U.S.A arrow
                            AACR Annual meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : VLP-based Peanut Allergy Vaccine

                            Therapeutic Area : Immunology

                            Study Phase : IND Enabling

                            Sponsor : Allergy Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            Allergy Therapeutics Selects AGC Biologics to Manufacture Peanut Allergy Vaccine Candidate

                            Details : Under the terms of the agreement, AGC Biologics is supporting the manufacturing and testing of Allergy Therapeutics’ VLP Peanut vaccine candidate, providing VLP material for Phase I supply.

                            Product Name : Undisclosed

                            Product Type : Vaccine

                            Upfront Cash : Undisclosed

                            March 31, 2022

                            Lead Product(s) : VLP-based Peanut Allergy Vaccine

                            Therapeutic Area : Immunology

                            Highest Development Status : IND Enabling

                            Sponsor : Allergy Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            AGC Biologics

                            U.S.A arrow
                            AACR Annual meeting
                            Not Confirmed

                            AGC Biologics

                            U.S.A arrow
                            AACR Annual meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Tozinameran

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Approved FDF

                            Sponsor : Pfizer Inc

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            AGC Biologics Inks Supply Deal for COVID-19 Vaccine

                            Details : AGC Biologics will manufacture and supply BioNTech with pDNA starting material, an essential component of BioNTech’s mRNA-based vaccine (BNT162b2) manufacturing process.

                            Product Name : BNT162b2

                            Product Type : Vaccine

                            Upfront Cash : Undisclosed

                            July 06, 2021

                            Lead Product(s) : Tozinameran

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Approved FDF

                            Sponsor : Pfizer Inc

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            AGC Biologics

                            U.S.A arrow
                            AACR Annual meeting
                            Not Confirmed

                            AGC Biologics

                            U.S.A arrow
                            AACR Annual meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Licaminlimab

                            Therapeutic Area : Ophthalmology

                            Study Phase : Phase II

                            Sponsor : Oculis

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            Oculis Selects AGC Biologics’ Heidelberg Facility to Manufacture OCS-02

                            Details : OCS-02 is a tumor necrosis factor-alpha (TNF alpha) inhibitor. TNF alpha is a proven biological target in ocular inflammation with possible dual actions: anti-inflammation and anti-necrosis.

                            Product Name : OCS-02

                            Product Type : Antibody

                            Upfront Cash : Undisclosed

                            June 05, 2021

                            Lead Product(s) : Licaminlimab

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Phase II

                            Sponsor : Oculis

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            AGC Biologics

                            U.S.A arrow
                            AACR Annual meeting
                            Not Confirmed

                            AGC Biologics

                            U.S.A arrow
                            AACR Annual meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : RP-L102

                            Therapeutic Area : Rare Diseases and Disorders

                            Study Phase : Phase II

                            Sponsor : Rocket Pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            AGC Biologics Expands Partnership with Rocket Pharmaceuticals

                            Details : Through the expanded partnership, AGC Biologics will bolster the security of supply of Rocket Pharmaceuticals across their entire lentiviral vector (LVV) pipeline, with the manufacture of LVV, which includes RP-L102 genetically modified with a lentiviral...

                            Product Name : RP-L102

                            Product Type : Cell and Gene therapy

                            Upfront Cash : Undisclosed

                            April 20, 2021

                            Lead Product(s) : RP-L102

                            Therapeutic Area : Rare Diseases and Disorders

                            Highest Development Status : Phase II

                            Sponsor : Rocket Pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            AGC Biologics

                            U.S.A arrow
                            AACR Annual meeting
                            Not Confirmed

                            AGC Biologics

                            U.S.A arrow
                            AACR Annual meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ER-004

                            Therapeutic Area : Rare Diseases and Disorders

                            Study Phase : Phase I

                            Sponsor : Pierre Fabre

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            Pierre Fabre Selects AGC Biologics as CDMO to Manufacture the Orphan Drug ER-004

                            Details : AGC Biologics will manufacture GMP material for the next stage of clinical trial. ER-004 is an intra-amniotic drug that will pioneer the treatment of a rare and debilitating genetic disorder.

                            Product Name : ER-004

                            Product Type : Protein

                            Upfront Cash : Undisclosed

                            December 21, 2020

                            Lead Product(s) : ER-004

                            Therapeutic Area : Rare Diseases and Disorders

                            Highest Development Status : Phase I

                            Sponsor : Pierre Fabre

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            AGC Biologics

                            U.S.A arrow
                            AACR Annual meeting
                            Not Confirmed

                            AGC Biologics

                            U.S.A arrow
                            AACR Annual meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Teprotumumab

                            Therapeutic Area : Immunology

                            Study Phase : Approved FDF

                            Sponsor : Horizon Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            AGC Biologics and Horizon Therapeutics plc Expand Partnership

                            Details : Horizon’s TEPEZZA® (teprotumumab-trbw) treatment will be produced from AGC Biologics’ new facility in Boulder. The facility is well equipped for the production of TEPEZZA. Following approval, it is expected that the facility will produce the majorit...

                            Product Name : Tepezza

                            Product Type : Antibody

                            Upfront Cash : Undisclosed

                            October 29, 2020

                            Lead Product(s) : Teprotumumab

                            Therapeutic Area : Immunology

                            Highest Development Status : Approved FDF

                            Sponsor : Horizon Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth